San Diego-based Sangart has raised $50 million from its Series F. The money comes from the exercise of warrants issued in 2007 and it brings the total amount of cash raised in the investment round to $100 million.
"This funding contributes significantly to our efforts to further the clinical research and development of our MP4 oxygen therapeutic products," said CEO Brian O'Callaghan. The MP4 molecule is the basis for Sangart's oxygen therapeutic product platform, which targets delivering oxygen to tissue threatened with oxygen deprivation.
- check out the press release on Sangart
ALSO: Switzerland's Kenta Biotech today announced that it raised $10 million in a Series B private financing from existing investors. The proceeds will be used for the ongoing clinical development of KBPA 101 in nosocomial pneumonia and to advance KBSA 201, a fully human IgG monoclonal antibody against methicilin-resistant Staphylococcus aureus, from preclinical into clinical development. Release